A party asserting an incorrect construction of a contract while remaining willing to perform on its proper construction does not repudiate the contract, and a claim for loss of a valuable commercial opportunity in respect of early-stage pharmaceutical IP requires admissible evidence of quantum and cannot succeed where the most likely outcome is that the invention would never reach human trials.
The full text is available to signed-in members, including the 1 later case that cites this judgment.